Page 7 - Gilead Life Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Covid-19: Govt waives import duty on Remdesivir injection, raw materials

The government on Tuesday waived customs duty on a key coronavirus (Covid-19) drug Remdesivir and its raw materials to lower cost amid a sharp increase in demand in the country. According to a notification from the customs department, the duty waiver was for Remdesivir injection, Remdesivir API and Beta Cyclodextrin, a key input, till October 31, 2021. Commerce and Industry Minister Piyush Goyal in a statement said, “In line with Prime Minister Narendra Modi’s priority to ensure affordable medical care for Covid-19 patients, imports of Remdesivir API, injection and specific inputs have been made import duty free. This should increase supply and reduce cost thus providing relief to patients.

Beta cyclodextrinZydus cadilaNarendra modiPiyush goyalGilead life sciencesIndustry minister piyush goyalPrime minister narendra modiDrug controller generalHetero healthcareJubilant genericsஜய்துச் காடிலாநரேந்திர மோடிபியூஷ கோயல்கிலியட் வாழ்க்கை அறிவியல்தொழில் அமைச்சர் பியூஷ கோயல்ப்ரைம் அமைச்சர் நரேந்திர மோடி

Low production in January, February led to shortage of Remdesivir | Hyderabad News

It’s not just the sudden spike in Covid-19 cases that has resulted in an acute shortage of anti-viral drug Remdesivir. One of the key reasons behind t

Andhra pradeshZydus cadilaMahesh doshiCipla ltdJubliant life sciencesBiocon group syngeneIndian drug manufacturer associationIndian drug manufacturerGilead life sciencesHetero drugsBiocon groupHyderabad newsHyderabad latest newsHyderabad news liveHyderabad news todayToday news hyderabad

Cancer API Market - Company Profile, Growth Strategies, Scope, Industry Updates, Size, Share, Challenges and Regional Outlook to 2023

Cancer API Market - Company Profile, Growth Strategies, Scope, Industry Updates, Size, Share, Challenges and Regional Outlook to 2023
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.

Bristol myers squibbMarket research consulting servicesEisai ltdOffice noBoehringer ingelheimTesaro incPuma biotech incyte corporationTakeda pharmaceutical companyAriad pharmaceuticals takedaExelixis incMarket research futurePfizer incResearch newswireAbbvie incBayer agResearch report

The market for Diffuse Large B-cell Lymphoma is skyrocketing and predicted to grow at a CAGR of 15% during forecast period 2020-2030, estimates DelveInsight

Share this article LAS VEGAS, Jan. 12, 2021 /PRNewswire/ DelveInsight s Diffuse Large B-cell Lymphoma Market Research Report report delivers thorough comprehension of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology along with the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The DLBCL market report provides analysis of current Diffuse Large B-cell Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs. Diffuse Large B-cell Lymphoma Market Report s Few Key Highlights CAR-T therapies and the pipeline agents, Lisocabtagene maraleucel, are expected to contribute significantly to revenues because of the premium pricing and clinical benefits in Relapsed-Refractory (R/R) patients.

United statesUnited kingdomShruti thakurKaryopharm selinexorBrentuximab vedotinLoncastuximab tesirineDenovo biopharmaPrnewswire delveinsightBristol myers squibbImbruvica ibrutinibCelgene bristol myers squibbCellectar bioscienceMorphosys incyteDebiopharm internationalJanssen pharmacyclics abbvie companyDiffuse large lymphoma market research

Exclusive | Jubilant Life Sciences Looking To Tap PE Funds For Pharma Business, Raise $500 Million

Exclusive | Jubilant Life Sciences Looking To Tap PE Funds For Pharma Business, Raise $500 Million
moneycontrol.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from moneycontrol.com Daily Mail and Mail on Sunday newspapers.

United statesAndhra pradeshHaris bhartiaShyams bhartiaSuven pharmaBiocon biologicsGoldman sachsJubilant life sciencesNational company law tribunalSuven life sciencesJubilant life sciences ltdJubilant pharma ltd singaporeGilead life sciencesNational stock exchangeLife chairman shyamManaging director haris bhartia